Patent classifications
A61K9/4841
METHODS OF TREATING NASH
The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Quinoline compounds as IRAK inhibitors and uses thereof
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
Dietary supplement
A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine and GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter.
A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS
- Robert Yongxin Zhao ,
- Qingliang YANG ,
- Jun LEI ,
- Yuanyuan HUANG ,
- Linyao ZHAO ,
- Hangbo YE ,
- Shun GAI ,
- Mingjun CAO ,
- Qianqian TONG ,
- Lu BAI ,
- Zhixiang GUO ,
- Chengyu YANG ,
- Xiaomai ZHOU ,
- Hongsheng XIE ,
- Yifang XU ,
- Huihui GUO ,
- Junxiang JIA ,
- Jun ZHENG ,
- Cheng LIN ,
- Xiaotao ZHUO ,
- Wenjun LI ,
- Yong DU ,
- Xiangfei KONG ,
- Binbin CHEN ,
- Yanlei YANG ,
- Yanhong TONG ,
- Xiaoxiao CHEN ,
- Yanhua LI ,
- Xiuzheng ZHANG ,
- Juan LAI
Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.
REMOTELY TRIGGERED THERAPY
This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection. In an embodiment, this disclosure provides a particle heater comprising a carrier admixed with a material that interacts with an exogenous source; wherein the material absorbs and converts the energy from the exogenous source into heat, then the heat travels outside the particle heater to induce localized hyperthermia at a temperature sufficient to selectively kill unwanted cells, and further wherein the particle heater structure is constructed such that it passes the Extractable Cytotoxicity Test.
IRON SUPPLEMENT COMPOSITIONS AND METHODS OF USE THEREOF
The disclosure is directed to iron supplement compositions comprising elemental metal iron and methods of replenishing a subject's iron, ferritin, and/or hemoglobin levels.
SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
IN SITU RECRUITMENT, REPROGRAMMING, AND RELEASE OF CAR-T CELLS
Disclosed are hydrogel matrixes for use in recruitment and reprogramming of CAR T cells, CAR NK cells, CAR NK T cells, CAR macrophage, Tumor infiltrating NK cells, tumor infiltrating lymphocytes, and marrow infiltrating lymphocytes.
Compositions and methods for the treatment of “plaques and tangles” in humans and animals
Composition and methods for treating brain “plaques” and/or “tangles” in a subject wherein the method comprises administration of a therapeutically effective amount of a composition comprising a black currant extract, Uncaria tomentosa extract, and an oolong tea extract.
TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS FOR TREATMENT OF RENAL DISEASE
Methods of treating renal disease or treating at least one of muscle wasting, low muscle strength, or low physical function in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating symptoms as a result of secondary hypogonadism induced by renal replacement therapy or kidney failure in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound. The methods of treatment disclosed herein also include co-administration of the tetrahydrocyclopenta[b]indole compound with a second composition